U.S. stock market midday update: Gelteq falls nearly 10%, trading volume surges, market sentiment fluctuations attract attention

U.S. Stock Market Midday Update Gelteq, down 9.91%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Eli Lilly down 3.63%, with increased trading volume. Based on recent key news: On January 13, Eli Lilly announced plans to acquire the French biotech company Abivax for $17.5 billion, which, if successful, will expand its influence in Europe and acquire key R&D assets. This news pushed Abivax's stock price up by 6.1%, but Eli Lilly's stock price rose slightly by 0.4%. Source: Zhitong Finance On January 13, Eli Lilly and NVIDIA announced a joint investment of $1 billion over the next five years to establish an AI drug development laboratory aimed at accelerating the drug development process. This move demonstrates the potential of AI in the medical field, although there have not yet been significant breakthroughs. Source: Yicai On January 12, Eli Lilly expressed confidence in the launch preparations for its new weight loss drug Orforglipron, expecting approval for market launch this quarter. This drug has received FDA priority review status, significantly shortening the review cycle. Source: Zhitong Finance. The AI medical market is expected to reach $155.3 billion by 2030. Novo Nordisk down 3.34%. Based on recent news: On January 14, Novo Nordisk's CEO stated that the company would take significant steps in seeking weight loss drug deals. This news raised market concerns about the company's future acquisition strategy, leading to a drop in stock price. On January 14, Novo Nordisk's CEO anticipated that international business would face some headwinds by 2026. Market concerns about the company's future international business intensified, further pushing down the stock price. On January 14, Novo Nordisk's CEO indicated that losing exclusive operating rights in multiple markets could lead to a challenging year for the company. Investor concerns about the company's future profitability increased, putting pressure on the stock price. Competition in the weight loss drug market is intensifying, with fierce price wars. Johnson & Johnson up 0.38%. Based on recent key news: On January 13, Johnson & Johnson's CEO stated that the company would focus on early-stage deals in 2026 and has sufficient financial strength to seize opportunities. This statement boosted investor confidence in the company's future growth, driving the stock price up. On January 15, Scotiabank analyst Louise Chen maintained a buy rating on Johnson & Johnson with a target price of $230. The analyst's positive rating further supported the upward trend in stock price. On January 14, Johnson & Johnson's TECVAYLI monotherapy showed better survival rates than standard treatment, reducing the risk of disease progression by 71% and the risk of death by 40%. This positive clinical result enhanced market confidence in the company's products, promoting stock price growth. Demand in the medical industry is growing, with clear policy support Stocks Ranked Among the Top in Industry Market Value AstraZeneca fell by 2.07%. Based on recent news, On January 13, AstraZeneca announced the acquisition of biomedical artificial intelligence company Modella AI, aiming to accelerate the development of oncology drugs. This move integrates Modella AI's multimodal foundational models and AI agents into AstraZeneca's oncology drug development system, helping to expedite clinical development. Following this announcement, the stock price experienced fluctuations. On January 13, due to the launch of the "Billion Cell Atlas" by Menarini, an alliance was formed with companies like AstraZeneca to promote drug target validation and AI model training. This news may impact AstraZeneca's research and development collaborations, leading to stock price fluctuations. On January 14, AstraZeneca's Chief Financial Officer discussed the company's merger and acquisition strategy and weight loss drug portfolio at the JP Morgan Healthcare Conference, predicting that 2026 will be a catalyst year for the company, with multiple high-value late-stage readouts expected to drive stock price fluctuations. AstraZeneca has been frequently involved in acquisitions and research collaborations recently, and the market is paying attention to its future developments